175 related articles for article (PubMed ID: 16508601)
1. [Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
Levy A; Guitera P; Kerob D; Ollivaud L; Archimbaud A; Dubertret L; Basset-Seguin N
Ann Dermatol Venereol; 2006 Feb; 133(2):157-60. PubMed ID: 16508601
[TBL] [Abstract][Full Text] [Related]
2. Metastatic melanoma: a regional review and future directions.
Khan KH; Goody RB; Hameed H; Jalil A; Coyle VM; McAleer JJ
Tumori; 2012; 98(5):575-80. PubMed ID: 23235751
[TBL] [Abstract][Full Text] [Related]
3. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
[TBL] [Abstract][Full Text] [Related]
5. Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.
Frosch PJ; Czarnetzki BM; Macher E; Grundmann E; Gottschalk I
J Cancer Res Clin Oncol; 1979; 95(3):281-6. PubMed ID: 528568
[TBL] [Abstract][Full Text] [Related]
6. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
7. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
[TBL] [Abstract][Full Text] [Related]
8. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
9. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Kiebert GM; Jonas DL; Middleton MR
Cancer Invest; 2003; 21(6):821-9. PubMed ID: 14735685
[TBL] [Abstract][Full Text] [Related]
11. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
12. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
13. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Hillner BE; Agarwala S; Middleton MR
J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of temozolomide in metastatic choroidal melanoma.
Bedikian AY; Papadopoulos N; Plager C; Eton O; Ring S
Melanoma Res; 2003 Jun; 13(3):303-6. PubMed ID: 12777987
[TBL] [Abstract][Full Text] [Related]
15. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Van Dyk JJ; Falkson G
Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel in combination with dacarbazine in patients with advanced melanoma.
Bafaloukos D; Aravantinos G; Fountzilas G; Stathopoulos G; Gogas H; Samonis G; Briasoulis E; Mylonakis N; Skarlos DV; Kosmidis P
Oncology; 2002; 63(4):333-7. PubMed ID: 12417787
[TBL] [Abstract][Full Text] [Related]
17. DTIC therapy in metastatic malignant melanoma: a simplified dose schedule.
Pritchard KI; Quirt IC; Cowan DH; Osoba D; Kutas GJ
Cancer Treat Rep; 1980; 64(10-11):1123-6. PubMed ID: 7459898
[TBL] [Abstract][Full Text] [Related]
18. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
19. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
Philip PA; Souliotis VL; Harris AL; Salisbury A; Tates AD; Mitchell K; van Delft JH; Ganesan TS; Kyrtopoulos SA
Clin Cancer Res; 1996 Feb; 2(2):303-10. PubMed ID: 9816173
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy of disseminated malignant melanoma with imidazol carboxamide (DTIC) and cyclophosphamide. Preliminary results.
Rudolf Z; Plesnicar S
Anticancer Res; 1982; 2(1-2):37-9. PubMed ID: 7051959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]